TABLE 2

Results for resurvey patients

Initial surveyResurveyp-valueResurvey HIV-positiveResurvey HIV-negativep-value
Subjects284284135150
Cough#92 (32.4)94 (33.0)0.92934 (25.2)60 (40.0)0.008
Haemoptysis#11 (3.9)21 (7.4)0.111 (8.1)10 (6.7)0.657
Fatigue#138 (48.6)89 (31.2)<0.00140 (29.6)49 (32.7)0.610
Fevers#74 (26.1)26 (9.1)<0.00112 (8.9)14 (9.3)1
Severe dyspnoea#57 (20.1)3 (1.1)<0.0013 (2.2)00.105
Night sweats#98 (34.5)51 (17.9)<0.00122 (16.3)29 (19.3)0.539
Chest pain#163 (57.4)76 (26.7)<0.00131 (23.0)45 (30.0)0.227
Cavitation46 (16.2)50 (17.5)0.73720 (14.8)30 (20.0)0.277
New cavitation4 (1.4)3 (2.2)1 (0.7)0.346
Deterioration of pre-existing cavitation3 (1.1)3 (2.2)00.104
All progressive cavitation7 (2.5)6 (4.4)1 (0.7)0.055
Paracavitary fibrosis24 (8.5)36 (12.6)0.13315 (11.1)21 (14.0)0.481
New paracavitary fibrosis12 (4.2)4 (3.0)8 (5.3)0.387
Deterioration of pre-existing paracavitary fibrosis6 (2.1)3 (2.2)3 (2.0)1
All progressive paracavitary fibrosis18 (6.3)7 (5.2)11 (7.3)0.627
Pleural thickening44 (15.5)50 (17.5)0.57320 (14.8)30 (20.0)0.277
New pleural thickening6 (2.1)3 (2.2)3 (2.0)1
Deterioration of pre-existing pleural thickening10 (3.5)3 (2.2)7 (4.7)0.343
All progressive pleural thickening16 (5.6)6 (4.4)10 (6.7)0.453
Fungal ball9 (3.2)13 (4.6)0.5154 (3.0)9 (6.0)0.265
New fungal ball4 (1.4)2 (1.5)2 (1.3)1
Deterioration of pre-existing fungal ball3 (1.1)1 (0.7)2 (1.3)1
All progressive fungal ball7 (2.5)3 (2.2)4 (2.7)1
Any radiological progression34 (11.9)15 (11.1)19 (12.7)0.718
Aspergillus IgG >20 mg·L−115 (5.3)28 (9.8)0.0569 (6.7)19 (12.7)0.111

Data are presented as n or n (%), unless otherwise stated. #: present for ≥1 month. All p-values calculated by Fisher's exact test. p<0.05 considered significant.